Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

entities : Anavex life sciences corp.    crawled time : 12:01    save search

Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Meets Primary and Secondary Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome
Published: 2020-12-15 (Crawled : 12:01) - globenewswire.com
AVXL | $3.45 -6.25% 700K twitter stocktwits trandingview |
Health Technology
| | O: 20.42% H: 2.08% C: -4.16%

life science trial phase 2 anavex®2-73 anavex syndros rett syndrome
Gainers vs Losers
54% 46%

Top 10 Gainers
CSSE 4 | $0.3499 129.74% 150M twitter stocktwits trandingview |
Consumer Services

CZOO | $11.04 121.24% 9.6M twitter stocktwits trandingview |

BOF | $2.05 75.21% 78M twitter stocktwits trandingview |

AMST | $3.2 60.0% 63M twitter stocktwits trandingview |
Technology Services

LICN | $0.8592 53.43% 13M twitter stocktwits trandingview |

WIMI | $1.05 44.75% 13M twitter stocktwits trandingview |
Technology Services

TROO | $1.51 38.53% 5.6M twitter stocktwits trandingview |
Manufacturing

MULN | News | $3.675 34.62% 11M twitter stocktwits trandingview |
Information

RILY | $27.91 28.5% 8.9M twitter stocktwits trandingview |
Finance

WHLM | $6.43 26.58% 580K twitter stocktwits trandingview |
Commercial Services


Your saved searches
Save your searches and get alerts when important news are released.